The recommendations in this guideline represent the view of NICE, arrived at after careful consideration of the evidence available. This guideline updates and replaces NICE technology appraisal guidance 25 (published May 2001). Adults aged 18 and over with pancreatic cancer, their families and carers.management for resectable, borderline resectable and unresectable cancer.monitoring for people with an inherited high risk of pancreatic cancer.This guideline includes recommendations on: See the COVID-19 rapid guideline: delivery of systemic anticancer treatments for more details.įor recommendations on identifying pancreatic cancer in primary care, or when to refer people to a specialist, see the NICE guideline on recognition and referral for suspected cancer. This may affect decisions for patients with pancreatic cancer. It aims to improve care by ensuring quicker and more accurate diagnosis, and by specifying the most effective treatments for people depending on how advanced their cancer is.Ī table of NHS England interim treatment regimens gives possible alternative treatment options for use during the COVID-19 pandemic to reduce infection risk. This guideline covers diagnosing and managing pancreatic cancer in adults aged 18 and over.

Download diagnosing pancreatic cancer